Episode Details
Back to Episodes
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
Published 1 year, 3 months ago
Description
Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.